| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovet...
Adhishthana.com analysis reveals why Zoetis stock may remain sluggish through June 2026, as weak triads weigh on its final phase.
UBS analyst Andrea Alfonso maintains Zoetis (NYSE:ZTS) with a Neutral and lowers the price target from $165 to $158.
Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) ...
https://www.fda.gov/news-events/press-announcements/fda-conditionally-approves-first-drug-prevention-and-treatment-new-world-sc...
https://www.ema.europa.eu/en/news/meeting-highlights-committee-veterinary-medicinal-products-cvmp-9-10-september-2025